RecruitingPhase 2NCT04322955
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Studying Chromophobe renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mark Stein
- Principal Investigator
- Mark N Stein, MDAssociate Professor of Medicine Division of Hematology/Oncology
- Intervention
- Cabozantinib(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2028
Study locations (4)
- The Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Columbia University Irving Medical Center, New York, New York, United States
- Cleveland Clinic, Cleveland, Ohio, United States
- Ohio State University Wexner Medical Center, Columbus, Ohio, United States
Collaborators
Exelixis · Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04322955 on ClinicalTrials.govOther trials for Chromophobe renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07485114Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsDaniel Keizman
- RECRUITINGPHASE3NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07233252Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerTianjin Medical University Second Hospital
- RECRUITINGNANCT07171190Targeted Abdominal CT in Conjunction With Lung Cancer ScreeningUniversity of Cambridge
- RECRUITINGPHASE2NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer SurgeryThe Methodist Hospital Research Institute
- RECRUITINGPHASE2NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialDerek W. Cool
- RECRUITINGNCT06889974Timing of Renal Replacement Therapy Initiation in Tumor Lysis SyndromeUniversity Hospital, Bordeaux
- ENROLLING BY INVITATIONNCT07307157Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewHarvard Medical School (HMS and HSDM)